C8ORF33

C8orf33 is a nuclear, predominantly nucleolar protein that functions as a determinant of DNA double-strand break (DSB) repair pathway choice, biasing repair toward non-homologous end joining (NHEJ) (PMID:41249114). Recruited to DSB sites in both nuclear and nucleolar chromatin, it facilitates 53BP1 accumulation and inhibits DNA end resection, thereby counteracting recruitment of the homologous recombination factors BRCA1 and RAD51 (PMID:41249114). Mechanistically, C8orf33 antagonizes chromatin association of the KAT8 acetyltransferase at break sites, lowering H4K16 acetylation; its loss enhances KAT8 binding and H4K16ac, shifting the balance toward HR factor recruitment and away from NHEJ (PMID:41249114). Consistent with this repair role, depletion destabilizes ribosomal DNA repeats and increases cell death, indicating a contribution to genome integrity (PMID:41249114). In hepatocellular carcinoma cells, C8orf33 supports proliferation, migration, and tumorigenicity while restraining apoptosis, in part through regulation of MIF and its receptor components CD74, CXCR4, and CD44 and associated tumor macrophage infiltration (PMID:41965457).

1. 2025 High

   Established that C8orf33 is a nucleolar/nuclear factor that actively governs DSB repair pathway choice, answering whether this uncharacterized ORF has a defined chromatin function.

   Evidence C8orf33 knockdown with live-cell localization and recruitment assays for 53BP1, BRCA1, and RAD51 at DSB sites

   PMID:41249114

   Open questions at the time

   • Direct molecular partners mediating 53BP1 facilitation are not defined
   • How C8orf33 is recruited to DSB sites is unknown
   • No structural basis for its activity
2. 2025 High

   Defined the chromatin-level mechanism by which C8orf33 enforces NHEJ — antagonizing KAT8 binding and H4K16 acetylation at breaks — answering how it tilts the resection balance.

   Evidence ChIP-based chromatin profiling plus loss-of-function measurement of KAT8 binding and H4K16ac at DSB sites

   PMID:41249114

   Open questions at the time

   • Whether C8orf33 binds KAT8 directly or acts through an intermediary is unresolved
   • No reconstitution of the antagonism in vitro
   • Stoichiometry and kinetics of KAT8 displacement unknown
3. 2025 Medium

   Linked the repair function to a cellular consequence, showing C8orf33 loss causes rDNA instability and cell death and thereby matters for genome maintenance.

   Evidence C8orf33 knockdown with rDNA repeat stability and viability/death assays

   PMID:41249114

   Open questions at the time

   • Single study and single lab
   • Whether rDNA loss is a direct consequence of aberrant HR or a secondary effect is not established
4. 2026 Medium

   Extended C8orf33 to a tumor-promoting role in hepatocellular carcinoma, connecting it to MIF–CD74/CXCR4/CD44 signaling and the tumor immune microenvironment.

   Evidence siRNA/shRNA knockdown in Huh7, xenograft assays, western blot/qPCR for MIF-axis components, IHC for macrophage markers

   PMID:41965457

   Open questions at the time

   • Single lab, correlative link between C8orf33 and MIF-axis regulation
   • Mechanism by which C8orf33 controls MIF/receptor expression is unknown
   • Relationship between the DSB-repair function and the HCC phenotype is not addressed

• How C8orf33 is recruited to DSBs, its direct binding partners, and whether its DNA-repair role mechanistically underlies its tumor-promoting effects remain unresolved.
• No identified direct protein interactor or recruitment determinant
• No structural or biochemical characterization
• DSB-repair function and HCC/MIF-axis phenotype not mechanistically connected